Citations

Clear

590 citation(s) found for "Ho, Ben".

Abstract 991: Development and characterization of patient derived xenografts from central nervous system metastasis reveal minor clone expansion linked with aggressive tumor behavior
Legendre, Christophe, Gooden, Gerald , Johnson, Kyle N., Petricoin, Emanuel F. , O’Shaughnessy, Joyce , Osborne, C., Bernstein, Mark, Salhia, Bodour , Tew, Ben Yi , Triche, Timothy J. , Martinez, Rae Anne , Pierobon, Mariaelena , Schroeder, Mark A. , Daniel, J. , Sarkaria, Jann N. , Toms, Steven A.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 991-991

10.1158/1538-7445.am2018-991 Get It

Abstract Despite recent advances in cancer therapy, options for central nervous system metastasis (CM) remain limited and patient outcomes are dismal. The lack of tumor models that reflect the heterogeneity and complexity of human CM tumors is a barrier to understanding the underlying biology and to developing novel therapies. Here, we report the development and characterization of 39 patient derived xenograft (PDX) models of CM tumors with histological subtypes representing the disease spectrum. The PDX models successfully grew both in the flank and brains of mice, and retained their histology regardless of the site of implantation. Brain metastasis also formed in 5/12 models after intra-cardiac injection. Multi-omic analysis of the PDX tumor and the patient-matched CM tumor showed that PDXs largely retained the molecular profiles of the tumor from which they were derived, including the retention of aberrations in key driver genes and signaling pathways. PDXs differed primarily from the ungrafted patient tumors by a downregulation in immunity-related pathways, which was expected due to the use of an immuno-compromised host, arguing for the validity of using the flank as a site of implantation. Integrated analysis of mutations and gene expression changes in CM revealed an upregulation of neuronal signaling and DNA damage response, and downregulation of calcium signaling and inflammation. We also assessed the clonal evolution of the PDX from the original patient CM by tracing variant allele frequencies in copy number neutral regions. We found that the PDX tumors were heterogeneous and comprised of multiple tumor clones that were either unique or in common with the original tumor, and displayed evidence of clonal expansion. Two PDXs that underwent phylogeny assessment showed evidence of minor clone expansion. One such PDX was a tumor from a Her2+ breast cancer (CM13), which largely did not molecularly resemble its matched patient tumor but was confirmed to have some shared expressed variants. The PDX was nearly copy number neutral, which included loss of the Her2 amplicon, and had few mutations compared with its parent tumor. Most noteworthy, is that CM13 displayed unique molecular patterns, aggressive growth and was highly metastatic in vivo. From the flank, it led to multiple metastases, including micrometastasis in the brain. This suggests that minor clone takeover may confer tumor aggressiveness and potentiate brain metastasis. The large and diverse repertoire of PDXs developed and characterized in this study provides a new set of tools that will help deepen our understanding of CM and improve preclinical testing for CM therapies. Our data also show that expansion of minor clones could confer aggressive tumor behavior and may be important in tumor evolution in PDX models and human cancers. Citation Format: Ben Yi Tew, Christophe Legendre, Tim Triche, Gerald C. Gooden, Kyle N. Johnson, Rae Anne Martinez, Emanuel F. Petricoin, Mariaelena Pierobon, Joyce O'Shaughnessy, Cindy Osborne, Mark A. Schroeder, Daniel J. Ma, Mark Bernstein, Jann N. Sarkaria, Steven A. Toms, Bodour Salhia. Development and characterization of patient derived xenografts from central nervous system metastasis reveal minor clone expansion linked with aggressive tumor behavior [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 991.
Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting
Shah, Paras , Patel, Vinay , George, Arvin K. , Alom, Manaf, Kozel, Zachary , Joshi, Vidhu B. , Ben‐Levi, Eran, Villani, Robert, Yaskiv, Oksana, Kavoussi, Louis R., Vira, Manish , Olsson, Carl O., Rastinehad, Ardeshir R. , Shah, Paras H , Joshi, Vidhu, Rastinehad, Ardeshir R , Moreira, Daniel M.

Mayo Clinic

BJU International | August 16, 2018 | Volume: 123 | Issue: 2 | Pages: 239-245

10.1111/bju.14515 | PMID 30113138 Get It

Objectives To investigate the impact of implementing magnetic resonance imaging (MRI) and ultrasonography fusion technology on biopsy and prostate cancer (PCa) detection rates in men presenting with clinical suspicion for PCa in the clinical practice setting. Patients and Methods We performed a review of 1 808 consecutive men referred for elevated prostate‐specific antigen (PSA) level between 2011 and 2014. The study population was divided into two groups based on whether MRI was used as a risk stratification tool. Univariable and multivariable analyses of biopsy rates and overall and clinically significant PCa detection rates between groups were performed. Results The MRI and PSA‐only groups consisted of 1 020 and 788 patients, respectively. A total of 465 patients (45.6%) in the MRI group and 442 (56.1%) in the PSA‐only group underwent biopsy, corresponding to an 18.7% decrease in the proportion of patients receiving biopsy in the MRI group ( P < 0.001). Overall PCa (56.8% vs 40.7%; P < 0.001) and clinically significant PCa detection (47.3% vs 31.0%; P < 0.001) was significantly higher in the MRI vs the PSA‐only group. In logistic regression analyses, the odds of overall PCa detection (odds ratio [OR] 1.74, 95% confidence interval [CI] 1.29–2.35; P < 0.001) and clinically significant PCa detection (OR 2.04, 95% CI 1.48–2.80; P < 0.001) were higher in the MRI than in the PSA‐only group after adjusting for clinically relevant PCa variables. Conclusion Among men presenting with clinical suspicion for PCa, addition of MRI increases detection of clinically significant cancers while reducing prostate biopsy rates when implemented in a clinical practice setting.
Frailty Phenotypes and Relations With Surgical Outcomes: A Latent Class Analysis
Sadiq, Furqaan, Wildes, Troy S. , McKinnon, Sherry, Sharma, Anshuman , Abdallah, Arbi Ben , Kronzer, Vanessa L. , Helsten, Daniel L. , Scheier, Lawrence Matthew , Avidan, Michael Simon

Mayo Clinic

Anesthesia & Analgesia | August 15, 2018 | Volume: 127 | Issue: 4 | Pages: 1017-1027

10.1213/ane.0000000000003695 | PMID 30113393 Get It

BACKGROUND: Frailty is an important concept in the care of older adults although controversy remains regarding its defining features and clinical utility. Both the Fried phenotype and the Rockwood deficit accumulation approaches cast frailty as a “burden” without exploring the relative salience of its cardinal markers and their relevance to the patient. New multifactorial perspectives require a reliable assessment of frailty that can validly predict postoperative health outcomes. METHODS: In a retrospective study of 2828 unselected surgical patients, we used item response theory to examine the ability of 32 heterogeneous markers capturing limitations in physical, functional, emotional, and social activity domains to indicate severity of frailty as a latent continuum. Eighteen markers efficiently indicated frailty severity and were then subject to latent class analysis to derive discrete phenotypes. Next, we validated the obtained frailty phenotypes against patient-reported 30-day postoperative outcomes using multivariable logistic regression. Models were adjusted for demographics, comorbidity, type and duration of surgery, and cigarette and alcohol consumption. RESULTS: The 18 markers provided psychometric evidence of a single reliable continuum of frailty severity. Latent class analyses produced 3 distinct subtypes, based on patients’ endorsement probabilities of the frailty indicators: not frail (49.7%), moderately frail (33.5%), and severely frail (16.7%). Unlike the moderate class, severely frail endorsed emotional health problems in addition to physical burdens and functional limitations. Models adjusting for age, sex, type of anesthesia, and intraoperative factors indicated that severely frail (odds ratio, 1.89; 95% confidence interval, 1.42–2.50) and moderately frail patients (odds ratio, 1.31; 95% confidence interval, 1.03–1.67) both had higher odds of experiencing postoperative complications compared to not frail patients. In a 3-way comparison, a higher proportion of severely frail patients (10.7%) reported poorer quality of life after surgery compared to moderately frail (9.2%) and not frail (8.3%) patients ( P < .001). There was no significant difference among these groups in proportions reporting hospital readmission (5.6%, 5.1%, and 3.8%, respectively; P = .067). CONCLUSIONS: Self-report frailty items can accurately discern 3 distinct phenotypes differing in composition and their relations with surgical outcomes. Systematically assessing a wider set of domains including limitations in functional, emotional, and social activities can inform clinicians on what precipitates loss of physiological reserve and profoundly influences patients’ lives. This information can help guide the current discussion on frailty and add meaningful clinical tools to the surgical practice.
Combinatorial engineering of N-TIMP2 variants that selectively inhibit MMP9 and MMP14 function in the cell
Arkadash, Valeria, Radisky, Evette S. , Papo, Niv , Radisky, Evette S

Mayo Clinic

Oncotarget | August 10, 2018 | Volume: 9 | Issue: 62 | Pages: 32036-32053

10.18632/oncotarget.25885 | PMID 30174795 Get It

Application of multi-state models in cancer clinical trials
Le‐Rademacher, Jennifer , Peterson, Ryan , Therneau, Terry M. , Sanford, Ben L. , Stone, Richard M. , Mandrekar, Sumithra J. , Le-Rademacher, Jennifer G , Peterson, Ryan A

Mayo Clinic

Clinical Trials | July 23, 2018 | Volume: 15 | Issue: 5 | Pages: 489-498

10.1177/1740774518789098 | PMID 30035644 Get It

Background/aims The goal of this article is to illustrate the utility of multi-state models in cancer clinical trials. Our specific aims are to describe multi-state models and how they differ from standard survival methods, to illustrate how multi-state models can facilitate deeper understanding of the treatment effect on multiple paths along the disease process that patients could experience in cancer clinical trials, to explain the differences between multi-state models and time-dependent Cox models, and to briefly describe available software to conduct such analyses. Methods Data from 717 newly diagnosed acute myeloid leukemia patients who enrolled in the CALGB 10603 trial were used as an illustrative example. The current probability-in-state was estimated using the Aalen–Johansen estimator. The restricted mean time in state was calculated as the area under the probability-in-state curves. Cox-type regression was used to evaluate the effect of midostaurin on the various clinical paths. Simulation was conducted using a newly constructed shiny application. All analyses were performed using the R software. Results Multi-state model analyses of CALGB 10603 suggested that the overall improvement in survival with midostaurin seen in the primary analysis possibly resulted from a higher complete remission rate in combination with a lower risk of relapse and of death after complete remission in patients treated with midostaurin. Simulation results, in a three-state illness-death without recovery model, demonstrate that multi-state models and time-dependent Cox models evaluate treatment effects from different frameworks. Conclusion Multi-state models allow detailed evaluation of treatment effects in complex clinical trial settings where patients can experience multiple paths between study enrollment and the final outcome. Multi-state models can be used as a complementary tool to standard survival analyses to provide deeper insights to the effects of treatment in trial settings with complex disease process.
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
Solomon, Scott D. , Rizkala, Adel R. , Lefkowitz, Martin, Shi, Victor , Gong, Jianjian , Anavekar, Nagesh S., Arango, Juan Luis, Arenas, J., Ben-Gal, T., Boytsov, S. А. , Chen, Chen-Huan, Cleland, John G.F. , DUENGEN, H, Echeverría, Luis Eduardo , Filippatos, Gerasimos , Flammer, Andreas J. , Galinier, Michel , Godoy, Armando, Gonçalvesová, Eva , Janssens, Stefan , Katova, Tzvetana, Køber, Lars , Lelonek, Małgorzata , Linssen, Gerard C.M. , Lund, Lars H. , O’Meara, Eileen , Perrone, Sergio V. , Ranjith, Naresh , Saito, Yoshihiko , Saraiva, Jose F. Kerr, Shah, Sanjiv J. , Seferović, Petar , Sibulo, Antonio S., Sim, David , Sweitzer, Nancy K. , Taurio, Jyrki , Vinereanu, Dragoş , Vrtovec, Bojan , Yılmaz, Mehmet Birhan , Zhou, Jingmin , Zweiker, Robert , Anand, Inder S. , Maggioni, Aldo P. , Pieske, Burkert , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk J. van , Zannad, Faı̈ez , Zile, Michael R. , McMurray, John J.V. , Felker, G. Michael , Zile, Michael R , Anand, Inder S , Maggioni, Aldo P , McMurray, John J V , Shah, Sanjiv J , Solomon, Scott David , Anker, Stefan D. , Atar, Dan , Chopra, Vijay , Comín‐Colet, Josep , Merkely, Béla , Miličić, Davor , Oh, Byung‐Hee , Senni, Michele , Sim, David , Jr., Jiri Widimsky , Ge, Junbo , Lam, Carolyn S.P. , Martínez‐Pastor, Felipe , Packer, Milton , Pfeffer, Marc Alan , Køber, Lars , Cleland, John G F

Mayo Clinic

Circulation: Heart Failure | July 6, 2018 | Volume: 11 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.118.004962 | PMID 29980595 Get It

Background: To describe the baseline characteristics of patients with heart failure and preserved left ventricular ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF) comparing sacubitril/valsartan to valsartan in reducing morbidity and mortality. Methods and Results: We report key demographic, clinical, and laboratory findings, and baseline therapies, of 4822 patients randomized in PARAGON-HF, grouped by factors that influence criteria for study inclusion. We further compared baseline characteristics of patients enrolled in PARAGON-HF with those patients enrolled in other recent trials of heart failure with preserved ejection fraction (HFpEF). Among patients enrolled from various regions (16% Asia-Pacific, 37% Central Europe, 7% Latin America, 12% North America, 28% Western Europe), the mean age of patients enrolled in PARAGON-HF was 72.7±8.4 years, 52% of patients were female, and mean left ventricular ejection fraction was 57.5%, similar to other trials of HFpEF. Most patients were in New York Heart Association class II, and 38% had ≥1 hospitalizations for heart failure within the previous 9 months. Diabetes mellitus (43%) and chronic kidney disease (47%) were more prevalent than in previous trials of HFpEF. Many patients were prescribed angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (85%), β-blockers (80%), calcium channel blockers (36%), and mineralocorticoid receptor antagonists (24%). As specified in the protocol, virtually all patients were on diuretics, had elevated plasma concentrations of N-terminal pro-B-type natriuretic peptide (median, 911 pg/mL; interquartile range, 464–1610), and structural heart disease. Conclusions: PARAGON-HF represents a contemporary group of patients with HFpEF with similar age and sex distribution compared with prior HFpEF trials but higher prevalence of comorbidities. These findings provide insights into the impact of inclusion criteria on, and regional variation in, HFpEF patient characteristics. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01920711.
Verteporfin-Loaded Poly(ethylene glycol)-Poly(beta-amino ester)-Poly(ethylene glycol) Triblock Micelles for Cancer Therapy
Kim, Jayoung , Shamul, James G., Shah, Sagar , Shin, Alyssa , Lee, Ben J., Quiñones‐Hinojosa, Alfredo , Green, Jordan J. , Shah, Sagar R, Green, Jordan J , Lee, Ben J

Mayo Clinic

Biomacromolecules | June 25, 2018 | Volume: 19 | Issue: 8 | Pages: 3361-3370

10.1021/acs.biomac.8b00640 | PMID 29940101 Get It

Abstract Amphiphilic polymers can be used to form micelles to deliver water-insoluble drugs. A biodegradable poly­(ethylene glycol) (PEG)-poly­(beta-amino ester) (PBAE)-PEG triblock copolymer was developed that is useful for drug delivery. It was shown to successfully encapsulate and pH-dependently release a water-insoluble, small molecule anticancer drug, verteporfin. PEG-PBAE-PEG micelle morphology was also controlled through variations to the hydrophobicity of the central PBAE block of the copolymer in order to evade macrophage uptake. Spherical micelles were 50 nm in diameter, while filamentous micelles were 31 nm in width with an average aspect ratio of 20. When delivered to RAW 264.7 mouse macrophages, filamentous micelles exhibited a 89% drop in cellular uptake percentage and a 5.6-fold drop in normalized geometric mean cellular uptake compared to spherical micelles. This demonstrates the potential of high-aspect-ratio, anisotropically shaped PEG-PBAE-PEG micelles to evade macrophage-mediated clearance. Both spherical and filamentous micelles also showed therapeutic efficacy in human triple-negative breast cancer and small cell lung cancer cells without requiring photodynamic therapy to achieve an anticancer effect. Both spherical and filamentous micelles were more effective in killing lung cancer cells than breast cancer cells at equivalent verteporfin concentrations, while spherical micelles were shown to be more effective than filamentous micelles against both cancer cells. Spherical and filamentous micelles at 5 and 10 μM respective verteporfin concentration resulted in 100% cell killing of lung cancer cells, but both micelles required a higher verteporfin concentration of 20 μM to kill breast cancer cells at the levels of 80% and 50% respectively. This work demonstrates the potential of PEG-PBAE-PEG as a biodegradable, anisotropic drug delivery system as well as the in vitro use of verteporfin-loaded micelles for cancer therapy.
Laparoscopic proximal gastrectomy for gastric neoplasms
Kukar, Moshim , Gabriel, Emmanuel , Ben‐David, Kfir , Hochwald, Steven N. , Gabriel, Emmanuel M

Mayo Clinic

Journal of Surgical Oncology | June 19, 2018 | Volume: 118 | Issue: 1 | Pages: 95-100

10.1002/jso.25123 | PMID 29920681 Get It

BackgroundFor cancers of the distal gastroesophageal junction or the proximal stomach, proximal gastrectomy can be performed. It is associated with several perioperative benefits compared with total gastrectomy. The use of laparoscopic proximal gastrectomy (LPG) has become an increasingly popular approach for select tumors.MethodsWe describe our method of LPG, including the preoperative work‐up, illustrated depictions of the key steps of the surgery, and our postoperative pathway.ResultsA total of 6 patients underwent LPG between July, 2013 to June, 2017. Five patients had early‐stage adenocarcinoma, and 1 patient had a gastrointestinal stromal tumor. The median age of the cohort was 70, and each patient had significant comorbidities. Conversion to open was required for 1 patient. All patients had negative final margins and an adequate lymph node dissection (median number of nodes examined was 15, range 12‐22). The median postoperative length of stay was 7 days (range 4‐7). Two patients developed anastomotic strictures requiring intervention, and 1 patient experienced significant reflux. At a median follow‐up of 11 months, there was 1 recurrence. Three patients were alive without evidence of disease, and 2 patients died from other causes.ConclusionsFor carefully selected patients, LPG is a safe and reasonable alternative to total gastrectomy, which is associated with similar oncologic outcomes and low morbidity.
Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing
Mansfield, Aaron S. , Mullane, Michael P., Mansfield, Aaron S , Park, Ben Ho

Mayo Clinic

American Society of Clinical Oncology Educational Book | June 8, 2018 | Volume: No volume available | Issue: 38 | Pages: 873-880

10.1200/edbk_208339 | PMID 30231389 Get It

Many targeted therapies—and, more recently, immunotherapies—have been approved by the U.S. Food and Drug Administration (FDA) with companion diagnostic tests. Next-generation sequencing (NGS) platforms are now approved to screen for many of these abnormalities, and they are increasingly being applied to guide therapeutic decision-making outside of these intended uses. The results provided by NGS testing can vary significantly based on the exact test performed and the analysis of the sequencing data. Given the complexities associated with interpreting NGS test results and acting on them, academic and community molecular tumor boards have been developed to provide multidisciplinary expertise for this endeavor. NGS test results may identify FDA-approved therapies, guide clinical trial recommendations, or prompt consideration of expanded access to investigational agents or off-label use of therapies approved for other indications. Many clinical trials now include NGS testing to assign treatments to patients based on the molecular profiles of their tumors. Although NGS testing may eventually help realize the development of individualized treatment regimens based on combinations of targeted therapies, the use of unproven and nonapproved combinations can be toxic and expensive. Given the increasing reliance on genetic biomarkers to guide therapeutic recommendations for FDA-approved therapies or enrollment into clinical trials, NGS will remain an integral part of the evolving medical oncology practice.
Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease
Yung, Diana E., Horesh, Nir , Ben‐Horin, Shomron , Eliakim, Rami, Koulaouzidis, Anastasios , Lightner, Amy L. , Kopylov, Uri

Mayo Clinic

Inflammatory Bowel Diseases | May 17, 2018 | Volume: 24 | Issue: 11 | Pages: 2327-2338

10.1093/ibd/izy156 | PMID 29788385 Get It